Siloton is developing a remote monitoring service utilizing integrated photonics technology to enable timely treatment for patients with age-related macular degeneration (AMD). This service addresses the issue of delayed care, which currently leads to preventable vision loss in one in four individuals over the age of 60.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related macular degeneration (AMD) affects a significant portion of the population over 60, often leading to preventable vision loss due to delays in treatment. Current monitoring methods do not facilitate timely intervention, resulting in irreversible damage for many patients.
Solution
Siloton is developing a remote monitoring service designed to enable more timely treatment for individuals with AMD. By leveraging integrated photonics technology, the service aims to provide continuous and convenient monitoring of patients' eye health. This approach allows for the early detection of changes indicative of disease progression, facilitating prompt intervention and potentially preventing further vision loss. The remote nature of the service reduces the need for frequent clinic visits, improving patient access to care and enabling more proactive management of AMD.
Target Audience
The primary target audience includes individuals over the age of 60 at risk of or diagnosed with age-related macular degeneration (AMD).
Features
- Remote monitoring of retinal health using integrated photonics technology.
- Early detection of changes associated with AMD progression.
- Continuous and convenient monitoring from the patient's home.